Sequencing Market - By Type (Next Generation Sequencing, Third Generation Sequencing, Sanger Sequencing, Global Sequencing), By Products And Services (Consumables, Sequencing Services, Instruments and Software, Global Sequencing) And By Region, Opportunities And Strategies – Global Forecast To 2023

Next-generation sequencing is a sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the genetic variation associated with diseases or other biological phenomena. The main products in the next-generation sequencing market are NextSeq systems, MiniSeq systems, NovaSeq systems, iSeq 100 systems, ion PGM Systems, Ion Proton systems, ion GeneStudio S5 systems, PacBio RS II Systems, sequel systems, and others. The MiniSeq system merges load-and-go operation with an intuitive user interface for a fast, easy NGS workflow. The MiniSeq System integrates clonal amplification, sequencing through synthesis, and base calling into a single benchtop instrument, preventing the requirement for additional equipment. The various technologies in next-generation sequencing are sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and other sequencing technologies that are used in diagnostics, drug discovery, and other applications. The global next generation sequencing market is segmented - 1) By Product: NextSeq Systems, MiniSeq Systems, NovaSeq Systems, iSeq 100 Systems, Ion PGM Systems, Ion Proton Systems, Ion GeneStudio S5 Systems, PacBio RS II Systems, Sequel Systems, Other Products 2) By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing, Other Sequencing Technologies 3) By Application: Diagnostics, Drug Discovery, Other Applications The global next generation sequencing market size will grow from $9.22 billion in 2022 to $10.44 billion in 2023 at a compound annual growth rate (CAGR) of 13.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global next generation sequencing is expected to grow to $17.32 billion in 2027 at a CAGR of 13.5%. The growing number of cases with chronic conditions such as cancer, AIDS, and thalassemia contributed to the growth of the next-generation sequencing market. Chronic illnesses and disorders are on the rise around the world, an aging population and shifts in social behavior lead to a gradual increase in these widespread and expensive long-term medical issues. Next-generation sequencing (NGS) is a versatile development tool utilized by researchers and clinicians across various cancer studies to recognize biomarkers that give guidance on treatments. The prevalence of chronic diseases is also expected to increase significantly, according to the World Health Organization. Hence, the increase in the number of chronic disease cases will increase the requirement for NGS sequencing and boosts revenues for the growth of next generation sequencing market. Major players in the next generation sequencing market are Illumina Inc., Thermo Fisher Scientific Inc., BGI Group, Agilent Technologies Inc., Qiagen N.V., Hoffmann-La Roche AG, Eurofins Scientific, Oxford Nanopore Technologies, Pacific Biosciences, and 10x Genomics. The high cost associated with next generation sequencing technologies is a key factor hampering the growth of the next-generation sequencing market. The next-generation sequencing market is facing challenges as many people find it difficult to afford the test due to the high cost. Consumables used for sequencing are the costliest portion of testing (68–72% of total cost) as machinery prices are higher in instances of rare disease. According to a review published on economic evaluations of exome and genome sequencing, the cost of next-generation genome sequencing ranges from $1906 to $24,810 for a single test. Therefore, the high cost of next-generation sequencing is anticipated to restrict market growth over the forecast period. Technological advances are shaping the next generation sequencing market. Major companies operating in the sequencing industry are focusing on developing technologically advanced solutions for next-generation sequencing. For instance, in 2020, Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System, which authorize simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day and also enabled further in which turnaround times for next-generation sequencing (NGS) results could be reduced to less than 24 hours. It also offers researchers the ability to profile 40 DNA targets and 29 fusion driver genes, authorizing observing more than 600 fusion isotypes to recognize biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia. North America was the largest region in the next generation sequencing market in 2022. Asia-Pacific was the second largest region in the global next generation sequencing market share. The regions covered in the global next generation sequencing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the next generation sequencing market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The next generation sequencing market consits of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductor sequencing, nano-pore sequencing, single-molecule real-time sequencing, and other technologies that are used for next generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The next generation sequencing market research report is one of a series of new reports from The Business Research Company that provides next generation sequencing market statistics, including next generation sequencing industry global market size, regional shares, competitors with a next generation sequencing market share, detailed next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing industry. This next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Synthetic biology is a field of biological science that involve engineering principles to redesign organisms to give them new abilities. It is possible to think of synthetic biology as the culmination or the prescriptive, deliberate stage of biology. The main product types of synthetic biology are oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organisms. Oligonucleotides are small single-stranded DNA segments that, when internalized by the cell, can specifically suppress the expression of a single protein. The various technologies include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering that are applied in pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others. The global synthetic biology market is segmented - 1) By Technology: Nucleotide Synthesis And Sequencing, Bioinformatics, Microfluidics, Genetic Engineering 2) By Application: Pharmaceuticals And Diagnostics, Chemicals, Biofuels, Bioplastics, Other Applications 3) By Product Type: Oligonucleotides, Enzymes, Cloning and Assembly Kits, Xeno-nucleic Acids (XNA), Chassis Organism The global synthetic biology market size will grow from $13.11 billion in 2022 to $17.07 billion in 2023 at a compound annual growth rate (CAGR) of 30.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global synthetic biology is expected to grow to $39.12 billion in 2027 at a CAGR of 23.0%. DNA sequencing is important in the development of the synthetic biology in many ways. DNA sequencing finds its use in many synthetic biology applications, therefore the availability of the DNA sequencing technique at low cost drives the production of products based on the applications of synthetic biology. DNA sequencing allows the researchers to determine the DNA sequences in genes and helps a researcher to create a repository of entire genomes. These repositories form the basis for the implementation of synthetic biology applications such as protein expression, directed evolution, and metabolic engineering. According to the Human Genome Research Institute, in 2021,, costs per genome sequenced have decreased from $3 billion to approximately $300 million over the past 17 years and are projected to be gradually lowered by 10 times over the next five years. Major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I. Du Pont De Nemours and Company, Koninklijke DSM N.V., Codexis, Merck KGaA, Danaher Corporation, EnBiotix, Evonetix, Prokarium, Eurofins Scientific, Origene technologies, Pareto Biotechnologies, Blue heron, Syntrox, ATUM, and DNA2.0. The bio-safety risks involved in synthetic biology restrains the synthetic biology market. Synthetic biology involves researches on micro-organism to perform the desired function or produce a biological desired substance. Such processes possess health risks such as illness, and allergies in humans as well as environmental risks such as toxicity and risk of new micro-organisms affecting living creatures in the ecosystem. Such potential risks pose as a deterrent to possible innovative research that could be done in certain fields such as combating epidemics such as Ebola and life-threatening diseases such as cancer. The new technological advances in the field of DNA sequencing has enabled the researchers to use DNA to store non-genetic information. With the rise in the demand to store quantum of data, DNA data storage offers a solution where one DNA strand can store about 455 Exabyte of data (455 billion gigabytes). Thus, the concept has received huge investments from the entities in the market. The binary data (data coded in 0O and 1) is converted into DNA strings of four potential base units of unique sequences of A, G, C, T (DNA is made up of four base components: Adenine, Guanine, Cytosine, and Thymine (known as AGCT)). The information coded in DNA lasts for thousands of years when compared to the data in traditional hard drives which gets corrupted or damaged within 30 years. For instance, according to a journal published by Nature Publishing Group, Microsoft and University of Washington researchers stored 35 distinct digital files in DNA—more than 200 megabytes of data and plans to increase future investment to improve the technology. In March 2020, Zymergen, a California-based material innovation company rethinking biology and reimagining the world acquired enEvolv, Inc. for an undisclosed amount. This acquisition speeds Zymergen delivery of high performance and sustainable products to customers and further cements Zymergen leadership position in the bio-manufacturing space. enEvolv, Inc., a next-generation synthetic biology company that has developed an enzyme and strain development platform to harness the power of evolution and create unique, commercial products by engineering the genomes of microbes. North America was the largest region in the synthetic biology market in 2022. Western Europe was the second largest region in the global synthetic biology market share. The regions covered in the global synthetic biology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The synthetic biology market includes revenue earned by synthetic compound, technology and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The synthetic biology market research report is one of a series of new reports from The Business Research Company that provides synthetic biology market statistics, including synthetic biology industry global market size, regional shares, competitors with a synthetic biology market share, detailed synthetic biology market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic biology industry. This synthetic biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others, and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies. The global viral vectors and plasmid dna market is segmented - 1) By Product: Plasmid DNA, Viral Vectors 2) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications 3) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies The global viral vectors & plasmid dna market size grew from $0.8 billion in 2022 to $0.91 billion in 2023 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the viral vectors & plasmid dna is expected to grow from $1.47 billion in 2027 at a CAGR of 12.6%. The rise in the global incidence of cancer is driving the viral vector and plasmid DNA market. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. According to the American cancer society 2020, an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States.Furthermore, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years. Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k???r??r?t??n, Cell and Gene Therapy Catapult, VGXI and MassBiologics. The unaffordable cost of gene therapies is a major challenge in the viral vectors and plasmid DNA market. The prices of gene therapies range from $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. The companies in the viral vectors and plasmid DNA market are focusing on the launch of viral vector assays to boost gene therapy research. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells and viral vector assays is an investigative procedure on viral vector. For example, in November 2022, PerkinElmer, an American testing laboratories company, announced the launch of its "ready-to-use" adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of diseases. The viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. In January 2020, Cognate Bioservices Inc., a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, which specialised in providing manufacturing services for plasmid DNA and viral vectors, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. North America is the largest region in the viral vectors and plasmid DNA market in 2022. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the global viral vectors & plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vectors & plasmid DNA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Microbiology diagnostics devices and equipment are a broad category covering all kinds of items used in microbiology laboratories and used to diagnose infectious diseases by examining pathogens. These devices and equipment included microscopes, slides, test tubes, Petri dishes, growth media (liquid and solid), inoculation loops, pipettes, and tips, incubators, autoclaves, and laminar flow hoods. Some pieces of equipment are permanent, like microscopes and hoods, while others are not, like pipette tips. The main types of microbiology diagnostic devices and equipment are laboratory instruments, and microbiology analyzers. Laboratory instruments are types of instruments such as incubators, gram stainers, bacterial colony counters, petri dish fillers, and automated culture systems that are needed for operations in the laboratories. The micro-biology analyzers involved are microbiology diagnostics instruments and microscopes. The reagents are pathogen-specific kits, and general reagents. The end-users involved are hospitals, diagnostic centres, customer lab service providers, academic institutes, and research institutes. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents The global microbiology diagnostic devices and equipment market size will grow from $3.94 billion in 2022 to $4.43 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiology diagnostic devices and equipment market size is expected to grow from $6.35 billion in 2027 at a CAGR of 9.4%. Increasing funding of public and private investments in medical devices is driving the growth of the microbiology diagnostic devices market. Increasing Investments indicate the rising confidence of various private and public players on microbiology diagnostic devices, thereby indicating a progressive increase and stimulating growth. For instance, according to MedTech news, a publisher of new related to medical technology, private equity industry invested $111.8 B (c.$ 151 B) in healthTech industry. Furthermore, globally 96 deals valued at $40.8 billion were completed in medTech vertical. The increasing investments in digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, and customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, and Charles River Laboratories International Inc. Unfavourable regulatory scenarios are major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug, and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous, and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as the capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration, and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next-Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to their cost effectiveness, sensitivity to detect low-frequency variants, and comprehensive genomic coverage. Next-Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with the ability to sequence hundreds to thousands of genes or gene regions and the capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, an NGS service that will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next-generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. On May 26th, 2022, The IVD Regulation seeks to ensure a high level of public health and patient safety taking into account scientific progress, and smooth operation of the single market for these products. These changes by the EU legislation aid in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In April 2022, DCN Dx, a US-based manufacturer and developer of point-of-use tests, acquired Biomed Diagnostics for an undisclosed amount. The acquisition would expand DCN Dx’s footprint in the vertical of point-of-use testing and sampling markets for both humans and animals.Biomed Diagnostics is a US-based microbiological testing company. North America was the largest region in the microbiology diagnostics devices and equipment market in 2022. Asia-Pacific was the second largest region in the global microbiology diagnostic devices and equipment market share. The regions covered in the global microbiology diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the microbiology diagnostics devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The microbiology diagnostic devices and equipment consists of sales of instruments such as incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen-specific kits, and general reagents for microbiology diagnostic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The microbiology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides microbiology diagnostics devices and equipment market statistics, including microbiology diagnostics devices and equipment industry global market size, regional shares, competitors with a microbiology diagnostics devices and equipment market share, detailed microbiology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the microbiology diagnostics devices and equipment industry. This microbiology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Transplant diagnostics are the tests conducted before relocation/ transplantation of the donor organ to the recipient patient. Histocompatibility and immunogenetics are the main topics of transplantation diagnostics in the context of organ transplantation and hematopoietic stem cell transplantation. The main types of transplant diagnostics market are reagents and consumables, instruments, and software and services. The transplant diagnostics instruments are products that are designed to speed up and improve the quality of transplant diagnostics. The technologies used in transplant diagnostics are non-molecular assay, and molecular assay to transplant various organs such as kidney, liver, heart, lung, and pancreas. The transplant types included are solid organ and stem cells that are used by end-users such as hospitals and transplant centres, research laboratories and transplant centres, and commercial service providers. The global transplant diagnostics market is segmented - 1) By Type: Reagent & Consumables, Instrument, Software & Services 2) By Transplant Type: Solid Organ, Stem Cell 3) By End User: Hospitals and Transplant Centers, Research Laboratories & Transplant Centers, Commercial Service Providers 4) By Technology: Non Molecular Assay, Molecular Assay 5) By Organ: Kidney, Liver, Heart, Lung, Pancreas The global transplant diagnostics market size grew from $1.66 billion in 2022 to $1.82 billion in 2023 at a compound annual growth rate (CAGR) of 9.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global transplant diagnostics is expected to grow from $2.4 billion in 2027 at a CAGR of 7.2%. Rising incidents of acute diseases are leading to an increase in organ failure rates, thus increasing the demand for transplant procedures driving the transplant diagnostics market. Organ transplant is a complex process and the success of the procedure depends on the acceptance of the donor's organ by the recipient's body system. To check whether the organ transplant can be successful, transplant diagnostic tests are performed. According to the United Network for Organ Sharing, a US-based non-private organization that manages organ transplantation in the US, in the year 2021, The U.S. saw a record-setting number of organ transplants. 24,669 kidney transplants, 9,236 liver transplants, and 3,817 heart transplantation procedures were performed in 2021. This high demand for diagnostic tests is driving the transplant diagnostics market. Major players in the transplant diagnostics market are Thermo Fisher ScientificInc., Illumina Inc., F. Hoffmann La-Roche AG., Abbott Laboratories Inc., Qiagen N.V., Immucor Transplant Diagnostics Inc., Bio-rad Laboratories Inc., Omixon Ltd., CareDx, Affymetrix Inc., and GenDx. A huge gap between organ donation and demand for organ transplantation is restraining the growth of the transplant diagnostics market. The number of organ donors is increasingly falling short of the number of people requiring organ transplantation. According to Health Resources and Services Administration in 2021, 106,090 people were on the waiting list for receiving organ donation. This is creating a huge deficit between the supply and demand of organ donors, with the number of people on the waiting list for organ transplants growing increasing with each passing year. This low number of organ donors is limiting the need for transplant diagnostic tests and devices, thus restraining the market growth. Companies in the transplant diagnostics market are using Next Generation Sequencing (NGS) for conducting tests to match organ donors and recipients. NGS technology allows the sequencing of an entire human genome, i.e. millions of DNA molecules within a single day. In Next-generation sequencing (NSG), genes are matched between the donor and recipient and depending on the extent of the match, a decision to perform organ transplantation is made. Nearly all transplant diagnostic tests and devices currently use this technology to decide on organ transplantation. For example, Castle Biosciences launched the Decision Dx-CMSeq Test that used NGS (Next Generation Sequencing) to identify somatic mutations in genes. The transplant diagnostics market is regulated by authorities such as the US Food and Drug Administration (FDA). For instance, companies in the transplant diagnostics market must comply with the Good Laboratories Practices (GLP) Part 58 directed by the FDA Title 21. According to this regulation, all the clinical instruments used to diagnose specimens must be maintained under specified conditions and should be properly calibrated, so that there should be minimal distortion in the result. The testing facility must be equipped with a quality assurance unit to monitor each piece of equipment, personnel, methods, practices, record, and controls. In August 2022, Eurobio Scientific, a France-based biotechnology company, acquired GenDx for $134.3 million(€135 million). The acquisition would help Eurobio to expand its research in the areas of transplantation. Genome Dx is a Netherlands-based molecular diagnostics startup. North America was the largest region in the transplant diagnostics market in 2022. Western Europe was the second largest region in the transplant diagnostics market report. The regions covered in the transplant diagnostics industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the transplant diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The transplant diagnostics market includes revenues earned by entities by PCR-based molecular assays, sequencing-based molecular assays, and non-molecular assay technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The transplant diagnostics market research report is one of a series of new reports from The Business Research Company that provides transplant diagnostics market statistics, including transplant diagnostics industry global market size, regional shares, competitors with a transplant diagnostics market share, detailed transplant diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the transplant diagnostics industry. This transplant diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Next generation sequencing (NGS) is a process used to determine the sequence of nucleotides in a section of DNA and is used in oncology research. NGS is used to identify rare cancer mutations and familial cancer mutation carriers and to provide molecular rationale for appropriate targeted therapy. The main technologies in clinical oncology next-generation sequencing are ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a technique of DNA sequencing found on the observation of hydrogen ions that are released throughout the polymerization of DNA. The clinical oncology next-generation sequencing is used in various applications such as screening, companion diagnostics, and other diagnostics that are used by various end-users such as hospital laboratories, clinical research organizations, and diagnostic laboratories. The global clinical oncology next-generation sequencing market is segmented - 1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing 2) By Application: Screening, Companion Diagnostics, Other Diagnostics 3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories The global clinical oncology next-generation sequencing market grew from $0.39 billion in 2022 to $0.45 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of clinical oncology next-generation sequencing is expected to grow from $0.75 billion in 2027 at a CAGR of 13.7%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the growth of the clinical oncology next-generation sequencing market. Major players in the clinical oncology next-generation sequencing market are Thermo Fisher Scientific (Qiagen), Oxford Nanopore Technologies, QIAGEN, Myriad Genetics, Illumina, F. Hoffmann-La Roche, Perkin Elmer, Agilent Technologies, Pacific Bioscience, and Caris Life Sciences. High costs associated with the clinical oncology next-generation sequencing are a major issue faced by patients across the globe. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In low-income countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low average life expectancy. According to an article published in 2020 by Genetics in Medicine, the genome sequencing costs per cancer case is around £6,841, and costs per rare disease are around £7,050, and this cost is due to consumables that are the most expensive components in the sequencing process, and the equipment cost for rare cancer disease is higher when compared with normal cancer equipment, thus restraining the growth of the market. Companies in the clinical oncology next-generation sequencing are increasingly investing in automation of workflow to increase precision and reduce the sample-to-sample variability. For instance, Agilent automation solutions have developed an automation system that allows increasing the number of reactions that can perform in parallel, reducing the amount of sample processing time, and increasing the number of samples which can be processed while reducing the variability amount from sample to sample. Companies such as Sophia Genetics are also investing in data-driven medicine that looks into automating DNA sequencing to better diagnose and treat patients. In April 2021, Agilent Technologies, a US-based life sciences technology company, acquired Resolution Bioscience for an undisclosed amount. The acquisition would expand Agilent's capabilities in the fields of next-generation sequencing for cancer diagnostics. Resolution Bioscience is a US-based developer of next-generation sequencing (NGS)-based precision oncology solutions. North America was the largest region in the clinical oncology next-generation sequencing market in 2022. Asia-Pacific was the second largest region in the global clinical oncology next-generation sequencing market share. The regions covered in the global clinical oncology next-generation sequencing market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the clinical oncology next-generation sequencing market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The clinical oncology next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides clinical oncology next-generation sequencing market statistics, including clinical oncology next-generation sequencing industry global market size, regional shares, competitors with a clinical oncology next-generation sequencing market share, detailed clinical oncology next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next-generation sequencing industry. This clinical oncology next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Human Microbiome Therapeutics Market Definition

Next Generation Sequencing Market Definition